FI103091B1 - Menetelmä viivästyneesti vapauttavan koostumuksen valmistamiseksi - Google Patents

Menetelmä viivästyneesti vapauttavan koostumuksen valmistamiseksi

Info

Publication number
FI103091B1
FI103091B1 FI922369A FI922369A FI103091B1 FI 103091 B1 FI103091 B1 FI 103091B1 FI 922369 A FI922369 A FI 922369A FI 922369 A FI922369 A FI 922369A FI 103091 B1 FI103091 B1 FI 103091B1
Authority
FI
Finland
Prior art keywords
pct
preparing
sustained release
release composition
sec
Prior art date
Application number
FI922369A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI103091B (fi
FI922369A0 (fi
FI922369A (fi
Inventor
Stephen Gordon Ring
David Brian Archer
Michael Charles Allwood
John Michael Newton
Original Assignee
British Tech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Tech Group filed Critical British Tech Group
Publication of FI922369A0 publication Critical patent/FI922369A0/fi
Publication of FI922369A publication Critical patent/FI922369A/fi
Application granted granted Critical
Publication of FI103091B publication Critical patent/FI103091B/fi
Publication of FI103091B1 publication Critical patent/FI103091B1/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Paints Or Removers (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Die Bonding (AREA)
  • Materials For Medical Uses (AREA)
  • Steroid Compounds (AREA)
  • Fats And Perfumes (AREA)
FI922369A 1989-11-24 1992-05-22 Menetelmä viivästyneesti vapauttavan koostumuksen valmistamiseksi FI103091B1 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898926639A GB8926639D0 (en) 1989-11-24 1989-11-24 Delayed release formulations
PCT/GB1990/001803 WO1991007949A1 (fr) 1989-11-24 1990-11-22 Compositions a liberation retardee

Publications (4)

Publication Number Publication Date
FI922369A0 FI922369A0 (fi) 1992-05-22
FI922369A FI922369A (fi) 1992-05-22
FI103091B FI103091B (fi) 1999-04-30
FI103091B1 true FI103091B1 (fi) 1999-04-30

Family

ID=10666886

Family Applications (1)

Application Number Title Priority Date Filing Date
FI922369A FI103091B1 (fi) 1989-11-24 1992-05-22 Menetelmä viivästyneesti vapauttavan koostumuksen valmistamiseksi

Country Status (17)

Country Link
US (1) US5294448A (fr)
EP (1) EP0502032B1 (fr)
JP (1) JP2975680B2 (fr)
KR (1) KR920703030A (fr)
AT (1) ATE103174T1 (fr)
CA (1) CA2069485C (fr)
DE (1) DE69007623T2 (fr)
DK (1) DK0502032T3 (fr)
ES (1) ES2053206T3 (fr)
FI (1) FI103091B1 (fr)
GB (2) GB8926639D0 (fr)
HU (1) HU209243B (fr)
NO (1) NO303424B1 (fr)
NZ (1) NZ236188A (fr)
RU (1) RU2093148C1 (fr)
WO (1) WO1991007949A1 (fr)
ZA (1) ZA909384B (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3034592B2 (ja) * 1990-11-20 2000-04-17 わかもと製薬株式会社 経口用固形製剤及びその製造法
DE4120918A1 (de) * 1991-06-25 1993-01-07 Basf Ag Pulverfoermige praeparate aus einer wasserunloeslichen kernsubstanz und einer schutzhuelle
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
EP0542299B1 (fr) * 1991-11-15 1999-08-04 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Polymères contenant des liaisons d'esters utilisés dans des préparations pharmaceutiques
US7070806B2 (en) 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US5514663A (en) * 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
US5565407A (en) * 1993-12-27 1996-10-15 University Of Kansas Center For Research, Inc. Biologically active agent encapsulated in biodegradable starch/polymer matrices
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5656294A (en) * 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US6004581A (en) * 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases
WO1997023199A1 (fr) * 1995-12-21 1997-07-03 Farmaceutisk Laboratorium Ferring A/S Composition pharmaceutique orale a liberation modifiee contenant 5-asa et procede de traitement de maladies intestinales
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
GB9722426D0 (en) * 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) * 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US8101200B2 (en) 2000-04-13 2012-01-24 Angiotech Biocoatings, Inc. Targeted therapeutic agent release devices and methods of making and using the same
CA2359812C (fr) * 2000-11-20 2004-02-10 The Procter & Gamble Company Formes posologiques pharmaceutiques a couches multiples permettant de reduire l'impact des revetement fractures
FI20002768A (fi) * 2000-12-18 2002-06-19 Licentia Oy Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus
CN1499960A (zh) * 2001-03-13 2004-05-26 ����˹��ҩ�﹫˾ 时间治疗剂型
US7771468B2 (en) * 2001-03-16 2010-08-10 Angiotech Biocoatings Corp. Medicated stent having multi-layer polymer coating
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
GB0203421D0 (en) * 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
WO2005027843A2 (fr) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Formes de dosage chronotherapeutique
EA200600598A1 (ru) * 2003-09-19 2006-08-25 Пенвест Фармасьютикалз Ко. Лекарственные формы замедленного высвобождения
AU2004311849B2 (en) * 2003-12-31 2009-04-02 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
KR100882756B1 (ko) * 2004-09-01 2009-02-09 더 프록터 앤드 갬블 캄파니 5-아미노-2-하이드록시벤조산 및 환원당을 함유하는 조성물
US20060165745A1 (en) * 2005-01-21 2006-07-27 Yiwen Chew Sustained release tablets for treatment of aqueous environment and methods for making the same
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
ES2524345T3 (es) 2007-04-04 2014-12-05 Sigmoid Pharma Limited Composición farmacéutica oral
TWI422398B (zh) * 2007-06-04 2014-01-11 Univ London 結腸給藥配方
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US8865688B2 (en) 2008-10-03 2014-10-21 Dr. Falk Pharma Gmbh Compositions and methods for treatment of bowel diseases with granulated mesalamine
ES2425762T3 (es) * 2008-10-27 2013-10-17 Roquette Freres Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon
EP2387580B1 (fr) 2009-01-14 2014-08-13 Novacta Biosystems Limited Dérivés de déoxyactagardine
JP5731407B2 (ja) 2009-02-04 2015-06-10 ノヴァクタ バイオシステムズ リミティッド アクタガルジン誘導体
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
EP2386297A1 (fr) * 2010-04-28 2011-11-16 Roquette Frères Non digérable polymère : Revêtements basé sur d'acetate d'amidon pour cibler le colon
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
RS55266B1 (sr) 2010-11-08 2017-02-28 Albireo Ab Ibat inhibitori za lečenje bolesti jetre
CN104302278B (zh) 2012-03-29 2018-08-21 塞拉拜姆有限责任公司 在回肠和阑尾上有活性的胃肠位点特异性口服接种疫苗制剂
JOP20200144A1 (ar) 2012-04-30 2017-06-16 Tillotts Pharma Ag تركيبة عقار ذو إطلاق متأخر
EP2968187A4 (fr) 2013-03-14 2016-08-17 Therabiome Llc Administration ciblée d'organismes probiotiques et/ou d'agents thérapeutiques dans le tractus gastro-intestinal
MY189394A (en) 2013-10-29 2022-02-09 Tillotts Pharma Ag A delayed release drug formulation
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
EP3215127B1 (fr) 2014-11-07 2020-10-28 Sublimity Therapeutics Limited Compositions comprenant de la cyclosporine
DE102015000795A1 (de) * 2015-01-23 2016-07-28 Se Tylose Gmbh & Co. Kg Reversibel vernetzte Celluloseether und Verfahren zu deren Herstellung durch selektive Oxidation von vicinalen OH-Gruppen
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) * 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
EP3664781A1 (fr) 2017-08-09 2020-06-17 Albireo AB Granules de cholestyramine, formulations orales de cholestyramine et leur utilisation
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2019245449A1 (fr) 2018-06-20 2019-12-26 Albireo Ab Formulation pharmaceutique à base d'odévixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
EP3662900A1 (fr) 2018-12-07 2020-06-10 Tillotts Pharma AG Formulation d'administration de médicament colonique
EP3662901A1 (fr) 2018-12-07 2020-06-10 Tillotts Pharma AG Formulation de medicaments a liberation ranlentie avec une couche exterieure comprenant un polymere degradable par des enzymes, sa composition et son processus de production
EP3662902A1 (fr) 2018-12-07 2020-06-10 Tillotts Pharma AG Formulation pour la liberation de médicaments dans le côlon
EP3662898A1 (fr) 2018-12-07 2020-06-10 Tillotts Pharma AG Formulation solide comprenant de la mésalamine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3360633D1 (en) * 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
US4755397A (en) * 1986-12-24 1988-07-05 National Starch And Chemical Corporation Starch based particulate encapsulation process
US4911952A (en) * 1987-07-10 1990-03-27 The United States Of America As Represented By The Secretary Of Agriculture Encapsulation by entrapment within matrix of unmodified starch
GB8812490D0 (en) * 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations

Also Published As

Publication number Publication date
DK0502032T3 (da) 1994-05-09
DE69007623D1 (de) 1994-04-28
GB9025373D0 (en) 1991-01-09
HUT62463A (en) 1993-05-28
EP0502032B1 (fr) 1994-03-23
ATE103174T1 (de) 1994-04-15
HU9201719D0 (en) 1992-08-28
ES2053206T3 (es) 1994-07-16
FI103091B (fi) 1999-04-30
RU2093148C1 (ru) 1997-10-20
NO922026L (no) 1992-07-23
FI922369A0 (fi) 1992-05-22
FI922369A (fi) 1992-05-22
NZ236188A (en) 1992-11-25
WO1991007949A1 (fr) 1991-06-13
CA2069485C (fr) 2000-04-18
GB2238243B (en) 1993-09-08
GB2238243A (en) 1991-05-29
DE69007623T2 (de) 1994-06-30
NO922026D0 (no) 1992-05-22
ZA909384B (en) 1992-07-29
EP0502032A1 (fr) 1992-09-09
JPH05504947A (ja) 1993-07-29
GB8926639D0 (en) 1990-01-17
US5294448A (en) 1994-03-15
NO303424B1 (no) 1998-07-13
HU209243B (en) 1994-04-28
KR920703030A (ko) 1992-12-17
JP2975680B2 (ja) 1999-11-10

Similar Documents

Publication Publication Date Title
FI103091B1 (fi) Menetelmä viivästyneesti vapauttavan koostumuksen valmistamiseksi
BR9611175B1 (pt) compostos e composiÇÕes farmacÊuticas.
NO955027D0 (no) Filmbelagt tablett av astemizol og pseudoefedrin, med forlenget frigivelse
DK0833611T3 (da) Sammensætning omfattende et aktivt middel opløst i en glasdannende bærer og fremgangsmåde til fremstilling heraf
AU5106996A (en) Process for producing active agent preparations in the form of a solid solution of the active agent in a polymer matrix and active agent preparations obtained thereby
FI113644B (fi) Menetelmä terapeuttisesti aktiivisten N-substituoitujen 3- atsabisykloalkaanijohdannaisten valmistamiseksi
DE69123159D1 (de) Therapeutische zusammensetzung und verfahren für ihre herstellung
ATE167690T1 (de) Polyetheramidoamine hydrogele als heparinersatz
ATE173399T1 (de) Retardtablette mit einem gehalt an diclofenac-na
ATE207480T1 (de) Substituierte aminoalkylaminopyridine
HU9401458D0 (en) Leukotriene-b4 derivatives, process for preparing the same and medicaments

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: ALIZYME THERAPEUTICS LIMITED

Free format text: ALIZYME THERAPEUTICS LIMITED